Iodobenzamide
From Wikipedia, the free encyclopedia
![]() |
|
Names | |
---|---|
IUPAC name
N-{[(2S)-1-Ethylpyrrolidin-2-yl]methyl}-2-hydroxy-3-iodo-6-methoxybenzamide
|
|
Other names
IBZM; Iolopride
|
|
Identifiers | |
84226-06-2 ![]() 113716-48-6 (123I) ![]() 113452-80-5 (125I) ![]() |
|
3D model (Jmol) | Interactive image |
ChemSpider | 123I).html 97107(123I) |
PubChem | 107995 |
|
|
|
|
Properties | |
C15H21IN2O3 | |
Molar mass | 404.25 g·mol−1 |
Pharmacology | |
V09AB02 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
Infobox references | |
IBZM (abbreviation for iodobenzamide) is a chemical substance. Pharmaceutically it is a dopamine antagonist and it can be used by nuclear medicine physicians as a radioactive tracer for SPECT where the radioactive isotope is iodine-123 or iodine-125.[1][2] The main purpose of a brain study with IBZM is the differentiation of Parkinson's disease from other neurodegenerative diseases such as Lewy Body dementia and multiple system atrophy.
References[edit]
- ^ Kung, H. F.; Guo, Y. Z.; Billings, J.; Xu, X.; Mach, R. H.; Blau, M.; Ackerhalt, R. E. (1988). "Preparation and biodistribution of [125I]IBZM: a potential CNS D-2 dopamine receptor imaging agent". Nuclear Medicine and Biology. 15 (2): 195–201. doi:10.1016/0883-2897(88)90088-8. PMID 2966782.
- ^ Kung, Hank, F.; Alavi; Chang; Kung; Keyes; Velchik; Billings; Pan; Noto (1990). "In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans". Journal of Nuclear Medicine. 31 (5): 573–579. PMID 2140408.
![]() |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |